262450-64-6

Basic information

• Product Name: (3-broMo-5-Methoxyphenyl)Methanol
• Synonyms: (3-broMo-5-Methoxyphenyl)Methanol;3-bromo-5-hydroxymethylanisole;3-Bromo-5-methoxybenzenemethanol
• CAS NO: 262450-64-6
• Molecular Formula: C₈H₉BrO₂
• Molecular Weight: 217.05986
• EINECS: -0
• Mol File: 262450-64-6.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 304.547 °C at 760 mmHg
• Flash Point: 137.985 °C
• Appearance: /
• Density: 1.513 g/cm³
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• CAS DataBase Reference: (3-broMo-5-Methoxyphenyl)Methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (3-broMo-5-Methoxyphenyl)Methanol(262450-64-6)
• EPA Substance Registry System: (3-broMo-5-Methoxyphenyl)Methanol(262450-64-6)

Safety Data

• Hazardous Substances Data: 262450-64-6(Hazardous Substances Data)

Usage

General Description

(3-bromo-5-methoxyphenyl)methanol is a chemical compound with the molecular formula C8H9BrO2. It is a white crystalline solid that is primarily used as an intermediate in the pharmaceutical industry for the synthesis of various drugs. (3-broMo-5-Methoxyphenyl)Methanol is also of interest in organic chemistry due to its potential applications in the development of new medicinal and pharmaceutical products. It is important to handle this compound with care, as it may be hazardous if not used properly.

Upstream product

• 157893-14-6 3-bromo-5-methoxybenzoic acid 
• 140472-69-1 3-bromo-5-hydroxy-benzoic acid 
• 262450-65-7 3-bromo-5-methoxybenzaldehyde 
• 56709-70-7 3-bromo-5-methoxy-benzoic acid methyl ester 
• 29578-83-4 3-bromo-5-methoxytoluene 

Downstream Products

• 59297-29-9 1-bromo-3-(bromomethyl)-5-methoxybenzene 
• 1260742-30-0 C₈H₈BrClO 
• 262450-78-2 1-(2-benzyloxybenzyl)-8-bromo-6-methoxy-2-propyl-1,2,3,4-tetrahydroisoquinoline 
• 262450-77-1 1-(2-benzyloxybenzyl)-8-bromo-6-methoxy-2-ethyl-1,2,3,4-tetrahydroisoquinoline 
• 262450-71-5 1-(2-benzyloxybenzyl)-6-bromo-8-methoxy-2-ethyl-1,2,3,4-tetrahydroisoquinoline 
• 262450-70-4 1-(2-benzyloxybenzyl)-6-bromo-8-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinoline 
• 262450-69-1 N-(3-bromo-5-methoxyphenethyl)-2-benzyloxyphenylacetamide 
• 262450-76-0 1-(2-benzyloxybenzyl)-8-bromo-6-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinoline 
• 262450-67-9 2-(3-bromo-5-methoxyphenyl)ethylamine 
• 262450-65-7 3-bromo-5-methoxybenzaldehyde 

Relevant articles and documents

SMALL MOLECULE AUTOPHAGY INDUCERS FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES

Disclosed herein are compounds and methods for treating cancer and neurodegenerative diseases. In some examples, the compounds increase autophagy.

Development of inhibitors against mycobacterium abscessus tRNA (m1G37) Methyltransferase (TrmD) Using Fragment-Based Approaches

Mycobacterium abscessus (Mab) is a rapidly growing species of multidrug-resistant nontuberculous mycobacteria that has emerged as a growing threat to individuals with cystic fibrosis and other pre-existing chronic lung diseases. Mab pulmonary infections are difficult, or sometimes impossible, to treat and result in accelerated lung function decline and premature death. There is therefore an urgent need to develop novel antibiotics with improved efficacy. tRNA (m1G37) methyltransferase (TrmD) is a promising target for novel antibiotics. It is essential in Mab and other mycobacteria, improving reading frame maintenance on the ribosome to prevent frameshift errors. In this work, a fragment-based approach was employed with the merging of two fragments bound to the active site, followed by structure-guided elaboration to design potent nanomolar inhibitors against Mab TrmD. Several of these compounds exhibit promising activity against mycobacterial species, including Mycobacterium tuberculosis and Mycobacterium leprae in addition to Mab, supporting the use of TrmD as a target for the development of antimycobacterial compounds.

8-Substituted isoquinoline derivative and the use thereof

The present invention relates to a compound represented by the following formula (1): wherein D1, A1, D2, R1, D3, and R2 each have the same meaning as defined in the present specification or a salt thereof. The compound represented by the formula (1) or a salt thereof has an IKKβ inhibiting activity and the like and is useful for the prevention and/or treatment of IKKβ-associated diseases or symptoms and the like.